Loading
A phase 2 trial of Selinexor in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT02227251 by Karyopharm Therapeutics Inc, with 244 participants planned, started 2014-11 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor, Selinexor, Selinexor. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Selinexor, Diffuse large B-cell lymphoma.
Shares Selinexor, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/